Enterococci are natural inhabitants of the gastrointestinal tract and of the female genital tract of humans and many animals. In recent years, enterococci have been increasingly recognized as important human pathogens causing infections associated with medical devices. Their resistance to most antimicrobial agents and their ability to form biofilm has contributed to the increasing incidence of nosocomial enterococcal infections. Enterococci possess a capsular polysaccharide composed of a glycerol-teichoic acid-like molecule consisting of repeating units of 6-α-D-glucose-1-2-glycerol-3-PO4, substituted on carbon 2 with a α-2,1-linked molecule of glucose. Using both immunologic and genetic data E. faecalis can be assigned to specific serotypes based on capsular polysaccharides. Clinical examples of foreign-body infections due to enterococci are described, comprising infections of artificial joints, implanted intravascular catheters, artificial hearts and artificial valves, stents, liquor shunt devices, and intraocular infections. Methods to prevent and/or treat enterococcal infections are presented.
HuyckeM.M., SahmD.F., GilmoreM.S.Multiple-drug resistant enterococci: The nature of the problem and an agenda for the future. Emerg Infect Dis1998; 4: 239–49.
2.
KayserF.H.Safety aspects of enterococci from the medical point of view. Int J Food Microbiol2003; 88: 255–62.
3.
FranzC.M., StilesM.E., SchleiferK.H., HolzapfelW.H.Enterococci in foods–a conundrum for food safety. Int J Food Microbiol2003; 88: 105–22.
4.
RichardsM.J., EdwardsJ.R., CulverD.H., GaynesR.P.Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect Control Hosp Epidemiol2000; 21: 510–5.
5.
FluitA.C., SchmitzF.J., VerhoefJ.Frequency of isolation of pathogens from bloodstream, nosocomial pneumonia, skin and soft tissue, and urinary tract infections occurring in European patients. Eur J Clin Microbiol Infect Dis2001; 20: 188–91.
6.
FridkinS., GaynesR.Antimicrobial resistance in intensive care units. Clin Chest Med1999; 20: 303–16.
LeclercqR., DerlotE., DuvalJ., CourvalinP.Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med1988; 319: 157–61.
10.
LewisK.Riddle of biofilm resistance. Antimicrob Agents Chemother2001; 45: 999–1007.
11.
O'TooleG., KaplanH.B., KolterR.Biofilm formation as microbial development. Annu Rev Microbiol2000; 54: 49–79.
12.
BaldassarriL., CecchiniR., BertucciniL., AmmendoliaM.G., IosiF., ArciolaC.R., MontanaroL., Di RosaR., GherardiG., DicuonzoG., OreficiG., CretiR.Enterococcus spp. produces slime and survives in rat peritoneal macrophages. Med Microbiol Immunol (Berl)2001; 190: 113–20.
13.
JoyanesP., PascualA., Martinez-MartinezL., HeviaA., PereaE.J.In vitro adherence of Enterococcus faecalis and Enterococcus faecium to plastic biomaterials. Clin Microbiol Infect1999; 5: 382–6.
14.
SuS.H., EatonJ.W., VeneziaR.A., TangL.Interactions of vancomycin resistant enterococci with biomaterial surfaces. ASAIO J1998; 44: 770–5.
15.
Toledo-AranaA., ValleJ., SolanoC., ArrizubietaM.J., CucarellaC., LamataM., AmorenaB., LeivaJ., PenadesJ.R., LasaI.The enterococcal surface protein, Esp, is involved in Enterococcus faecalis biofilm formation. Appl Environ Microbiol2001; 67: 4538–45.
16.
BosR., van der MeiH.C., BusscherH.J.Physico-chemistry of initial microbial adhesive interactions–its mechanisms and methods for study. FEMS Microbiol Rev1999; 23: 179–230.
17.
JeffersonK.K.What drives bacteria to produce biofilm?FEMS Microbiol Lett2004; 236: 163–73.
18.
BalabanN., GiacomettiA., CirioniO., GovY., GhiselliR., MocchegianiF., ViticchiC., Del PreteM.S., SabaV., ScaliseG., Dell'AcquaG.Use of the quorum-sensing inhibitor RNAIII-inhibiting peptide to prevent biofilm formation in vivo by drug-resistant Staphylococcus epidermidis. J Infect Dis2003; 187: 625–30.
OttoM., EchnerH., VoelterW., GotzF.Pheromone cross-inhibition between Staphylococcus aureus and Staphylococcus epidermidis. Infect Immun2001; 69: 1957–60.
21.
HancockL.E., PeregoM.The Enterococcus faecalis fsr two-component system controls biofilm development through production of gelatinase. J Bacteriol2004; 186: 5629–39.
22.
NakayamaJ., CaoY., HoriiT., SakudaS., AkkermansA.D., de VosW.M., NagasawaH.Gelatinase biosynthesis-activating pheromone: A peptide lactone that mediates a quorum sensing in Enterococcus faecalis. Mol Microbiol2001; 41: 145–54.
23.
QinX., SinghK.V., WeinstockG.M., MurrayB.E.Effects of Enterococcus faecalis fsr genes on production of gelatinase and a serine protease and virulence. Infect Immun2000; 68: 2579–86.
24.
PillaiS.K., SakoulasG., GoldH.S., WennerstenC., EliopoulosG.M., MoelleringR.C.Jr, Inouye RT. Prevalence of the fsr locus in Enterococcus faecalis infections. J Clin Microbiol2002; 40: 2651–2.
25.
SifriC.D., MylonakisE., SinghK.V., QinX., GarsinD.A., MurrayB.E., AusubelF.M., CalderwoodS.B.Virulence effect of Enterococcus faecalis protease genes and the quorum-sensing locus fsr in Caenorhabditis elegans and mice. Infect Immun2002; 70: 5647–50.
26.
SinghK.V., QinX., WeinstockG.M., MurrayB.E.Generation and testing of mutants of Enterococcus faecalis in a mouse peritonitis model. J Infect Dis1998; 178: 1416–20.
27.
NakayamaJ., CaoY., HoriiT., SakudaS., NagasawaH.Chemical synthesis and biological activity of the gelatinase biosynthesis-activating pheromone of Enterococcus faecalis and its analogs. Biosci Biotechnol Biochem2001; 65: 2322–5.
28.
HaasW., GilmoreM.S.Molecular nature of a novel bacterial toxin: The cytolysin of Enterococcus faecalis. Med Microbiol Immunol (Berl)1999; 187: 183–90.
29.
ShankarN., BaghdayanA.S., GilmoreM.S.Modulation of virulence within a pathogenicity island in vancomycin-resistant Enterococcus faecalis. Nature2002; 417: 746–50.
30.
HaasW., ShepardB.D., GilmoreM.S.Two-component regulator of Enterococcus faecalis cytolysin responds to quorum-sensing autoinduction. Nature2002; 415: 84–7.
31.
HuyckeM.M., GilmoreM.S.Frequency of aggregation substance and cytolysin genes among enterococcal endocarditis isolates. Plasmid1995; 34: 152–6.
32.
ArchimbaudC., ShankarN., ForestierC., BaghdayanA., GilmoreM.S., CharbonneF., JolyB.In vitro adhesive properties and virulence factors of Enterococcus faecalis strains. Res Microbiol2002; 153: 75–80.
33.
CoqueT.M., PattersonJ.E., SteckelbergJ.M., MurrayB.E.Incidence of hemolysin, gelatinase, and aggregation substance among enterococci isolated from patients with endocarditis and other infections and from feces of hospitalized and community-based persons. J Infect Dis1995; 171: 1223–9.
34.
JettB.D., JensenH.G., NordquistR.E., GilmoreM.S.Contribution of the pAD1-encoded cytolysin to the severity of experimental Enterococcus faecalis endophthalmitis. Infect Immun1992; 60: 2445–52.
35.
von EiffC., JansenB., KohnenW., BeckerK.Infections associated with medical devices. Drugs2005; 65: 179–214.
36.
ClewellD.B.Bacterial sex pheromone-induced plasmid transfer. Cell1993; 73: 9–12.
37.
SartingenS., RozdzinskiE., Muscholl-SilberhornA., MarreR.Aggregation substance increases adherence and internalization, but not translocation, of Enterococcus faecalis through different intestinal epithelial cells in vitro. Infect Immun2000; 68: 6044–7.
38.
KreftB., MarreR., SchrammU., WirthR.Aggregation substance of Enterococcus faecalis mediates adhesion to cultured renal tubular cells. Infect Immun1992; 60: 25–30.
39.
VanekN.N., SimonS.I., Jacques-PalazK., MariscalcoM.M., DunnyG.M., RakitaR.M.Enterococcus faecalis aggregation substance promotes opsonin- independent binding to human neutrophils via a complement receptor type 3-mediated mechanism. FEMS Immunol Med Microbiol1999; 26: 49–60.
40.
SussmuthS.D., Muscholl-SilberhornA., WirthR., SusaM., MarreR., RozdzinskiE.Aggregation substance promotes adherence, phagocytosis, and intracellular survival of Enterococcus faecalis within human macrophages and suppresses respiratory burst. Infect Immun2000: 68: 4900–6.
41.
ChowJ.W., ThalL.A., PerriM.B., VazquezJ.A., DonabedianS.M., ClewellD.B., ZervosM.J.Plasmid-associated hemolysin and aggregation substance production contribute to virulence in experimental enterococcal endocarditis. Antimicrob Agents Chemother1993; 37: 2474–7.
42.
SchlievertP.M., GahrP.J., AssimacopoulosA.P., DingesM.M., StoehrJ.A., HarmalaJ.W., HirtH., DunnyG.M.Aggregation and binding substances enhance pathogenicity in rabbit models of Enterococcus faecalis endocarditis. Infect Immun1998; 66: 218–23.
WaarK., van der MeiH.C., HarmsenH.J., DegenerJ.E., BusscherH.J.Adhesion to bile drain materials and physicochemical surface properties of Enterococcus faecalis strains grown in the presence of bile. Appl Environ Microbiol2002; 68: 3855–8.
45.
RichR.L., KreikemeyerB., OwensR.T., LaBrenzS., NarayanaS.V., WeinstockG.M., MurrayB.E., HookM.Ace is a collagen-binding MSCRAMM from Enterococcus faecalis. J Biol Chem1999; 274: 26939–45.
46.
NallapareddyS.R., SinghK.V., DuhR.W., WeinstockG.M., MurrayB.E.Diversity of ace, a gene encoding a microbial surface component recognizing adhesive matrix molecules, from different strains of Enterococcus faecalis and evidence for production of ace during human infections. Infect Immun2000; 68: 5210–7.
47.
LoweA.M., LambertP.A., SmithA.W.Cloning of an Enterococcus faecalis endocarditis antigen: Homology with adhesins from some oral streptococci. Infect Immun1995; 63: 703–6.
48.
SinghK.V., CoqueT.M., WeinstockG.M., MurrayB.E.In vivo testing of an Enterococcus faecalis efaA mutant and use of efaA homologs for species identification. FEMS Immunol Med Microbiol1998; 21: 323–31.
49.
LeavisH., TopJ., ShankarN., BorgenK., BontenM., van EmbdenJ., WillemsR.J.A novel putative enterococcal pathogenicity island linked to the esp virulence gene of Enterococcus faecium and associated with epidemicity. J Bacteriol2004; 186: 672–82.
50.
WastfeltM., Stalhammar-CarlemalmM., DelisseA.M., CabezonT., LindahlG.Identification of a family of streptococcal surface proteins with extremely repetitive structure. J Biol Chem1996; 271: 18892–7.
51.
MichelJ.L., MadoffL.C., OlsonK., KlingD.E., KasperD.L., AusubelF.M.Large, identical, tandem repeating units in the C protein alpha antigen gene, bca, of group B streptococci. Proc Natl Acad Sci USA1992; 89: 10060–4.
52.
CucarellaC., SolanoC., ValleJ., AmorenaB., LasaI., PenadesJ.R.Bap, a Staphylococcus aureus surface protein involved in biofilm formation. J Bacteriol2001; 183: 2888–96.
53.
ShankarV., BaghdayanA.S., HuyckeM.M., LindahlG., GilmoreM.S.Infection-derived Enterococcus faecalis strains are enriched in esp, a gene encoding a novel surface protein. Infect Immun1999; 67: 193–200.
54.
WillemsR.J., TopJ., van Den BraakN., van BelkumA., EndtzH., MeviusD., StobberinghE., van Den BogaardA., van EmbdenJ.D.Host specificity of vancomycin-resistant Enterococcus faecium. J Infect Dis2000; 182: 816–23.
55.
ShankarN., LockatellC.V., BaghdayanA.S., DrachenbergC., GilmoreM.S., JohnsonD.E.Role of Enterococcus faecalis surface protein Esp in the pathogenesis of ascending urinary tract infection. Infect Immun2001; 69: 4366–72.
HufnagelM., KochS., CretiR., BaldassarriL., HuebnerJ.A putative sugar-binding transcriptional regulator in a novel gene locus in Enterococcus faecalis contributes to production of biofilm and prolonged bacteremia in mice. J Infect Dis2004; 189: 420–30.
59.
WickenA., ElliottS., BaddileyJ.The identity of streptococcal group D antigen with teichoic acids. J Gen Microbiol1963; 31: 231–9.
60.
ElliottS.Teichoic acids and the group antigen of group D streptococci. Nature1962; 193: 1105–6.
61.
SharpeM.Serological types of Streptococcus faecalis and its varieties and their cell wall type antigen. J Gen Microbiol1964; 36: 151–60.
62.
MaekawaS., YoshiokaM., KumamotoY.Proposal of a new scheme for the serological typing of Enterococcus faecalis strains. Microbiol Immunol1992; 36: 671–81.
63.
MaekawaS., HabaderaS.Comparative distribution of the serotypes of Enterococcus faecalis isolated from the urine of patients with urinary tract infections and the feces of healthy persons as determined by the slide agglutination reaction. Kansenshogaku Zasshi1996; 70: 168–74.
64.
HuebnerJ., WangY., KruegerW.A., MadoffL.C., MartirosianG., BoisotS., GoldmannD.A., KasperD.L., TzianabosA.O., PierG.B.Isolation and chemical characterization of a capsular polysaccharide antigen shared by clinical isolates of Enterococcus faecalis and vancomycin-resistant Enterococcus faecium. Infect Immun1999; 67: 1213–9.
65.
HuebnerJ., QuaasA., KruegerW.A., GoldmannD.A., PierG.B.Prophylactic and therapeutic efficacy of antibodies to a capsular polysaccharide shared among vancomycin-sensitive and - resistant enterococci. Infect Immun2000; 68: 4631–6.
66.
WangY., HuebnerJ., TzianabosA.O., MartirosianG., KasperD.L., PierG.B.Structure of an antigenic teichoic acid shared by clinical isolates of Enterococcus faecalis and vancomycin-resistant Enterococcus faecium. Carbohydr Res1999; 316: 155–60.
67.
HancockL.E., GilmoreM.S.The capsular polysaccharide of Enterococcus faecalis and its relationship to other polysaccharides in the cell wall. Proc Natl Acad Sci USA2002; 99: 1574–9.
68.
XuY., JiangL., MurrayB.E., WeinstockG.M.Enterococcus faecalis antigens in human infections. Infect Immun1997; 65: 4207–15.
69.
XuY., MurrayB.E., WeinstockG.M.A cluster of genes involved in polysaccharide biosynthesis from Enterococcus faecalis OG1RF. Infect Immun1998; 66: 4313–23.
70.
XuY., SinghK.V., QinX., MurrayB.E., WeinstockG.M.Analysis of a gene cluster of Enterococcus faecalis involved in polysaccharide biosynthesis. Infect Immun2000; 68: 815–23.
71.
RaymondJ., HenryJ., WorkowskiK.A.Enterococcal arthritis: Case report and review. Clin Infect Dis1995; 21: 516–22.
72.
RiesM.D.Vancomycin-resistant Enterococcus infected total knee arthroplasty. J Arthroplasty2001; 16: 802–5.
73.
TillM., WixsonR.L., PertelP.E.Linezolid treatment for osteomyelitis due to vancomycin-resistant Enterococcus faecium. Clin Infect Dis2002; 34: 1412–4.
NathwaniD., McWhinneyP.M., PatelA., GreenS.T., KennedyD.H.Recurrent episodes of enterococcaemia from an infected Hickman line precipitated by ganciclovir infusion. Postgrad Med J1990; 66: 791.
76.
SahagunP.J., CastilloF.J., AndresR., CapillaS., MayordomoJ.I., PitartC., TresA.[Surveillance of commensal flora evolution and infections in neutropenic cancer patients submitted to chemoprophylaxis]. Rev Esp Quimioter2005; 18: 32–8.
77.
MalaniP.N., DykeD.B., PaganiF.D., ArmstrongW.S., ChenowethC.E.Successful treatment of vancomycin resistant Enterococcus faecium mediastinitis associated with left ventricular assist devices. Ann Thorac Surg2003; 76: 1719–20.
78.
MalaniP.N., DykeD.B., PaganiF.D., ChenowethC.E.Nosocomial infections in left ventricular assist device recipients. Clin Infect Dis2002; 34: 1295–300.
79.
SafdarA., BryanC.S., StinsonS., SaundersD.E.Prosthetic valve endocarditis due to vancomycin-resistant Enterococcus faecium: Treatment with chloramphenicol plus minocycline. Clin Infect Dis2002; 34: E61–3.
CarfagnaP., TarasiA., CassoneM., Del GrossoM.F., BiancoG., VendittiM.Prosthetic biologic valve endocarditis caused by a vancomycin-resistant (vanA) Enterococcus faecalis: Case report. J Chemother2000; 12: 416–20.
82.
MelhusA., TjernbergI.First documented isolation of vancomycin-resistant Enterococcus faecium in Sweden. Scand J Infect Dis1996; 28: 191–3.
83.
RaoN., WhiteG.J.Successful treatment of Enterococcus faecalis prosthetic valve endocarditis with linezolid. Clin Infect Dis2002; 35: 902–4.
84.
DysonC., BarnesR.A., HarrisonG.A.Infective endocarditis: An epidemiological review of 128 episodes. J Infect1999; 38: 87–93.
85.
LidjiM., RubinsteinE., SamraH.Bacterial endocarditis on a prosthetic valve. Oral treatment with amoxicillin. Chest1978; 74: 224–5.
86.
RerknimitrR., FogelE.L., KalayciC., EsberE., LehmanG.A., ShermanS.Microbiology of bile in patients with cholangitis or cholestasis with and without plastic biliary endoprosthesis. Gastrointest Endosc2002; 56: 885–9.
87.
DonelliG., PaolettiC., BaldassarriL., GuaglianoneE., Di RosaR., MagiG., SpinaciC., FacinelliB.Sex pheromone response, clumping, and slime production in enterococcal strains isolated from occluded biliary stents. J Clin Microbiol2004; 42: 3419–27.
88.
LeungJ.W., LiuY.L., DestaT., LibbyE., InciardiJ.F., LamK.Is there a synergistic effect between mixed bacterial infection in biofilm formation on biliary stents?Gastrointest Endosc1998; 48: 250–7.
89.
PintadoV., CabellosC., MorenoS., MeseguerM.A., AyatsJ., ViladrichP.F.Enterococcal meningitis: A clinical study of 39 cases and review of the literature. Medicine (Baltimore).2003; 82: 346–64.
90.
SchoenbaumS.C., GardnerP., ShillitoJ.Infections of cerebrospinal fluid shunts: Epidemiology, clinical manifestations, and therapy. J Infect Dis1975; 131: 543–52.
91.
TakayamaY., SunakawaK., AkahoshiT.Meningitis caused by Enterococcus gallinarum in patients with ventriculoperitoneal shunts. J Infect Chemother2003; 9: 348–50.
92.
ZarrougA.E., GolkarL., EachempatiS.R., BarieP.S.Vancomycin-resistant Enterococcus ventriculo-peritoneal shunt infection cured by monotherapy with chloramphenicol. Surg Infect (Larchmt)2003; 4: 289–91.
TanT.Y., PitmanI., Penrose-StevensA., SimpsonB.A., FlanaganP.G.Treatment of a vancomycin-resistant Enterococcus faecium ventricular drain infection with quinupristin/dalfopristin and review of the literature. J Infect2000; 41: 95–7.
95.
ZegansM.E., BeckerH.I., BudzikJ., O'TooleG.The role of bacterial biofilms in ocular infections. DNA Cell Biol2002; 21: 415–20.
HorioN., TerasakaH., HoriguchiM., YamamotE., MiyakeY.Vitrectomy for endophthalmitis after intraocular lens implantation. Jpn J Ophthalmol2000; 44: 439–42.
98.
EngelbertM., MylonakisE., AusubelF.M., CalderwoodS.B., GilmoreM.S.Contribution of gelatinase, serine protease, and fsr to the pathogenesis of Enterococcus faecalis endophthalmitis. Infect Immun2004; 72: 3628–33.
99.
MylonakisE., EngelbertM., QinX., SifriC.D., MurrayB.E., AusubelF.M., GilmoreM.S., CalderwoodS.B.The Enterococcus faecalis fsrB gene, a key component of the fsr quorum-sensing system, is associated with virulence in the rabbit endophthalmitis model. Infect Immun2002; 70: 4678–81.
100.
National Nosocomial Infections Surveillance (NNIS)System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control2004; 32: 470–85.
101.
KlareI., WitteW.Zum Auftreten und zur Verbreitung glycopeptidresistenter Enterokokken. Epidemiol Bull2005; 17: 149–55.
102.
CollinsL.A., MalanoskiG.J., EliopoulosG.M., WennerstenC.B., FerraroM.J., MoelleringR.C.Jr.. In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother1993; 37: 598–601.
103.
ShonekanD., HandwergerS., MildvanD.Comparative in-vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria. J Antimicrob Chemother1997; 39: 405–9.
104.
ChowJ.W., DonahedianS.M., ZervosM.J.Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia. Clin Infect Dis1997; 24: 90–1.
105.
DowzickyM., TalbotG.H., FegerC., ProkocimerP., EtienneJ., LeclercqR.Characterization of isolates associated with emerging resistance to quinupristin/dalfopristin (Synercid) during a worldwide clinical program. Diagn Microbiol Infect Dis2000; 37: 57–62.
106.
MoelleringR.C.Linezolid: The first oxazolidinone antimicrobial. Ann Intern Med2003; 138: 135–42.
107.
GonzalesR.D., SchreckenbergerP.C., GrahamM.B., KelkarS., DenBestenK., QuinnJ.P.Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet2001; 357: 1179.
108.
RaadI.I., HannaH.A., HachemR.Y., DvorakT., ArbuckleR.B., ChaibanG., RiceL.B.Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: A comparison with quinupristin-dalfopristin. Antimicrob Agents Chemother2004; 48: 3583–5.
109.
SabolK., PattersonJ.E., LewisJ.S.2nd, OwensA., CadenaJ., JorgensenJ.H.Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother2005; 49: 1664–5.
110.
GottenbosB., GrijpmaD.W., van der MeiH.C., FeijenJ., BusscherH.J.Antimicrobial effects of positively charged surfaces on adhering Gram-positive and Gram-negative bacteria. J Antimicrob Chemother2001; 48: 7–13.
111.
TillerJ.C., LiaoC.J., LewisK., KlibanovA.M.Designing surfaces that kill bacteria on contact. Proc Natl Acad Sci USA2001; 98: 5981–5.
112.
FrancoliniI., NorrisP., PiozziA., DonelliG., StoodleyP.Usnic acid, a natural antimicrobial agent able to inhibit bacterial biofilm formation on polymer surfaces. Antimicrob Agents Chemother2004; 48: 4360–5.
113.
PaulsenI.T., BanerjeiL., MyersG.S., NelsonK.E., SeshadriR., ReadT.D., FoutsD.E., EisenJ.A., GillS.R., HeidelbergJ.F., TettelinH., DodsonR.J., UmayamL., BrinkacL., BeananM., DaughertyS., DeBoyR.T., DurkinS., KolonayJ., MadupuR., NelsonW., VamathevanJ., TranB., UptonJ., HansenT., ShettyJ., KhouriH., UtterbackT., RaduneD., KetchumK.A., DoughertyB.A., FraserC.M.Role of mobile DNA in the evolution of vancomycin-resistant Enterococcus faecalis. Science2003; 299: 2071–4.
114.
RhinehartE., SmithN.E., WennerstenC., GorssE., FreemanJ., EliopoulosG.M., MoelleringR.C.Jr., GoldmannD.A.Rapid dissemination of beta-lactamase-producing, aminoglycoside- resistant Enterococcus faecalis among patients and staff on an infant- toddler surgical ward. N Engl J Med1990; 323: 1814–8.
